Contact
info@topadur.com+41 44 755 44 66Topadur Pharma AG
Grabenstrasse 11A
8952 Schlieren, Switzerland
Grabenstrasse 11A
8952 Schlieren, Switzerland
Zurich-Schlieren, Switzerland, November 10, 2020. TOPADUR Pharma AG, a biopharmaceutical start-up company today announces positive results from an analysis of the first two dose groups of the ongoing Phase 1 clinical of TOP-N53, a first-in-class wound healing drug candidate. The safety results from this interim analysis of the first two dose groups suggest that the drug was safe and well-tolerated. Moreover, data from the first two groups demonstrated an increase in skin microcirculation.
“These first results support the important role of TOP-N53 in the treatment of chronic wounds exemplified by diabetic foot ulcer (DFU) and digital ulcers (DU)”, said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG.
A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts.
Read moreTopical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.
Read moreTOPADUR Pharma AG announces dosing of first healthy subjects in Phase 1 clinical trial of TOP-N53.
Read more
